Immune interference in the setting of same-day administration of two similar inactivated alphavirus vaccines: Eastern equine and western equine encephalitis

Vaccine

Volumn 30, Issue 50, 2012, Pages 7271-7277

  Reisler, Ronald B ^a   Gibbs, Paul H ^a   Danner, Denise K ^a   Boudreau, Ellen F ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Eastern equine encephalitis vaccine; Plaque reduction neutralization test (PRNT); Western equine encephalitis vaccine

Indexed keywords

EASTERN EQUINE ENCEPHALITIS VACCINE; ENCEPHALITIS VACCINE; FORMALDEHYDE; INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; WESTERN EQUINE ENCEPHALITIS VACCINE;

ADULT; ANIMAL CELL; ANTIBODY TITER; ARTICLE; DRUG ADMINISTRATION; EASTERN EQUINE ENCEPHALITIS; EASTERN EQUINE ENCEPHALOMYELITIS VIRUS; EMBRYO; FEMALE; GENDER; HUMAN; IMMUNE INTERFERENCE; IMMUNE RESPONSE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SAME DAY VACCINE ADMINISTRATION; SEPARATE DAY VACCINE ADMINISTRATION; SEX DIFFERENCE; VIRUS NEUTRALIZATION; WESTERN EQUINE ENCEPHALITIS; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS;

ADOLESCENT; ADULT; AGED; ALPHAVIRUS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DRUG CARRIERS; DRUG INTERACTIONS; ENCEPHALITIS VIRUS, EASTERN EQUINE; ENCEPHALITIS VIRUS, WESTERN EQUINE; ENCEPHALOMYELITIS, EASTERN EQUINE; ENCEPHALOMYELITIS, WESTERN EQUINE; FEMALE; GENETIC VECTORS; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; VACCINATION; VIRAL PLAQUE ASSAY; VIRAL VACCINES; YOUNG ADULT;

EID: 84869886596     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.049     Document Type: Article

References (48)

1. Smith D.W., Mackenzie J.S., Weaver S.C. Alphaviruses. Clinical virology 2009, 1241-1274. ASM Press, Washington DC. 3rd ed. D.D. Richman, R.J. Whitley, F.G. Hayden (Eds.).
2. Griffin D.E. Alphaviruses. Fields virology 2007, 1023-1067. Lippincott, Williams, and Wilkins, Philadelphia. 5th ed. D.M. Knipe, P.M. Howley (Eds.).
3. Weaver S.C., Paessler S. Alphaviral encephalitides. Vaccines for biodefense and emerging and neglected diseases 2009, 340-359. Elsevier Inc, Amsterdam. A.D. Barrett, L.R. Stanberry (Eds.).
4. Hachiya M., Osborne M., Stinson C., Werner B.G. Human eastern equine encephalitis in Massachusetts: predictive indicators from mosquitoes collected at 10 long-term trap sites, 1979-2004. Am J Trop Med Hyg 2007, 76:285-292.
5. Randall R., Maurer F.D., Smadel J.E. Immunization of laboratory workers with purified Venezuelan equine encephalomyelitis vaccine. J Immunol 1949, 63(3):313-318.
6. Pittman P., Plotkin S.A. Biodefense and special pathogen vaccines. Vaccines 2008, 1123-1133. Elsevier, Philadelphia, PA. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
7. Cole F.E., McKinney R.W. Cross-protection in hamsters immunized with group A arbovirus vaccines. Infec Immun 1971, 4:37-43.
8. Calisher C.H., Sasso D.R., Sather G.E. Possible evidence for interference with Venezuelan equine encephalitis virus vaccination of equines by pre-existing antibody to eastern or western equine encephalitis virus, or both. Appl Microbiol 1973, 26:485-488.
9. Pittman P.R., Liu C.T., Cannon T.L., Mangiafico J.A., Gibbs P.H. Immune interference after sequential alphavirus vaccine vaccinations. Vaccine 2009, 27:4879-4882.
10. Centers for disease control and prevention. General recommendations on immunization: recommendations of the advisory committee on immunization practices (ACIP). MMWR 2011; 60(RR02):1-60.
11. Maire L.F., McKinney R.W., Cole F.E. An inactivated eastern equine encephalomyelitis vaccine propagated in chick-embryo cell culture. I. Production and testing. Am J Trop Med Hyg 1970, 190:119-122.
12. Bartelloni P.J., McKinney R.W., Calia F.M., Ramsburg H.H., Cole F.E. Inactivated western equine encephalomyelitis vaccine propagated in chick embryo cell culture: clinical and serological evaluation in man. Am J Trop Med Hyg 1971, 20:146-149.
13. Rusnak J.M., Boudreau E.F., Hepburn M.J., Martin J.W., Bavari S. Medical countermeasures. Medical aspects of biological warfare 2007, 465-513. Office of the Surgeon General, Falls Church, VA. Z.F. Dembek (Ed.).
14. Mangiafico J.A., Sanchez J.L., Figueiredo L.T., LeDuc J.W., Peters C.J. Isolation of a newly recognized Bunyawera serogroup virus from a febrile human in Panama. Am J Trop Med Hyg 1988, 39:593-596.
15. Hepburn M.J., Kortepeter M.G., Pittman P.R., Boudreau E.F., Mangiafico J.A., Buck P.A., et al. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine 2006, 24:2843-2849.
16. SAS Institute Incorporated. Cary, NC;, 2009.
17. McClain D.J., Pittman P.R., Ramsburg H.H., Nelson G.O., Rossi C.A., Mangiafico J.A., et al. Immunologic interference from sequential administration of live attenuated Alphavirus vaccines. J Infect Dis 1998, 177:634-641.
18. Bell J.R., Kinney R.M., Trent D.W., Strauss E.G., Strauss J.H. An evolutionary tree relating eight alphaviruses, based on amino terminal sequences of their glycoproteins. Proc Natl Acad Sci USA 1984, 81:4702-4706.
19. Fine D.L., Jenkins E., Martin S.S., Glass P., Parker M.D., Grimm B. A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV). J Virol Methods 2010, 163(2):424-432.
20. Kruijsen D., Schijf M.A., Lukens M.V., van Uden N.O., Kimpen J.L., Coenjaerts F.E., et al. Local innate and adaptive immune responses regulate inflammatory cell influx into the lungs after vaccination with formalin inactivated RSV. Vaccine 2011, 29(15):2730-2741.
21. Tiwari M., Parida M., Santhosh S.R., Khan M., Dash P.K., Rao P.V. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 2009, 27(18):2513-2522.
22. Budimir N., Huckriede A., Meijerhof T., Boon L., Gostick E., Price D.A., et al. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity. PLoS One 2012, 7(1):e30898.
23. Davis E.G., Zhang Y., Tuttle J., Hankins K., Wilkerson M. Investigation of antigen specific lymphocyte responses in healthy horses vaccinated with an inactivated West Nile virus vaccine. Vet Immunol Immunopathol 2008, 126(3-4):293-301.
24. Yashima S., Yoshizaki S., Shinoda K., Yoshida A., Kondo A., Mizuguchi H., et al. Co-administration of viral vector-based vaccines suppresses antigen-specific effector CD8T cells. Vaccine 2010, 28:3257-3264.
25. Hodge J.W., Higgins J., Schlom J. Harnessing the unique local immunostim ulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diver-sified prime and boost vaccine regimen. Vaccine 2009, 27:4475-4482.
26. Pittman P.R., Makuch R.S., Mangiafico J.A., Cannon T.L., Gibbs P.H., Peters C.J. Long-term duration of detectable neutralizing antibodies after administration of live attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 1996, 14:337-343.
27. Rusnak J.M., Gibbs P., Boudreau E., Clizbe D.P., Pittman P. Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study. Vaccine 2011, 29:3222-3229.
28. Cook I.F. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 2008, 26:3551-3555.
29. Kennedy R.B., Ovsyannikova I.G., Pankratz V.S., Vierkant R.A., Jacobson R.M., Ryan M.A., et al. Gender effects on humoral immune responses to smallpox vaccine. Vaccine 2009, 27(25-26):3319-3323. Epub 2009 Feb 5.
30. Sex differences in the vaccine-specific and non-targeted effects of vaccines-conference report. Vaccine 2011; 29:2349-2354.
31. Kao T.M., Hsieh S.M., Kung H.C., Lee Y.C., Huang K.C., Huang L.M., et al. Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly. Vaccine 2010, 28:6159-6163.
32. Zeeshan M., Jabeen K., Ali A.N.A., Ali A.W., Farooqui S.Z., Mehraj V., et al. Evaluation of immune response to hepatitis B vaccine in health care workers at a tertiary care hospital in Pakistan: an observational prospective study. BMC Infect Dis 2007, 7:120.
33. Green M.S., Shohat T., Lerman Y., Astemborski J., Margolick J.B., Quinn T.C. Sex differences in the humoral antibody response to live measles vaccine in young adults. Int J Epidemiol 1994, 23:1078-1081.
34. Engler R.J., Nelson M.R., Klote M.M., VanRaden M.J., Huang C., Cos N.J., et al. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Int Med 2008, 168:2405-2414.
35. Torres A.J.L., Angelo A.L.D., Netto E.M., Sampaio G.P., Souza D.F.C., Inocêncio L.A., et al. Reference range for T lymphocytes populations in blood donors from two different regions in Brazil. Brazil J Infect Dis 2009, 13(3):221-225.
36. Mair C., Hawes S.E., Agne H.D., Sow P.S., N'doye I., Manhart L.E., et al. Factors associated with CD4 lymphocyte counts in HIV-negative Senegalese individuals. Clin Exp Immunol 2008, 151(3):432-440. Epub 2008 Jan 10.
37. Wikby A., Månsson I.A., Johansson B., Strindhall J., Nilsson S.E. The immune risk profile is associated with age and gender: findings from three Swedish population studies of individuals 20-100 years of age. Biogerontology 2008, 9(5):299-308. Epub 2008 Mar 28.
38. Hewagama A., Patel D., Yarlagadda S., Strickland F.M., Richardson B.C. Stronger inflammatory/cytotoxic T-cell response in women identified by microarray analysis. Genes Immun 2009, 10(5):509-516. Epub 2009 Mar 12.
39. Pennell L.M., Galligan C.L., Fish E.N. Sex affects immunity. J Autoimmun 2012, 38(2-3):J282-J291.
40. Loza M.J., Foster S., Bleecker E.R., Peters S.P., Penn R.B. Asthma and gender impact accumulation of T cell subtypes. Respir Res 2010, 11:103.
41. Bandell A., Woo J., Coelingh K. Protective efficacy of live attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference. Expert Rev Vaccines 2011, 10(8):1131-1141.
42. Pollabauer E.M., Petermann R., Ehrlich H.J. The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infants. Vaccine 2009, 27:1674-1679.
43. Dagan R., Poolman J., Siegrist C.A. Glycoconjugate vaccines and immune interference: a review. Vaccine 2010, 28:5513-5523.
44. Prevnar 13 [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Corp; Dec 2011.
45. MacIntyre C.R., Egerton T., McCaughey M., Parrino J., Campbell B.V., Su S.C., et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old. Hum Vaccin 2010, 6(11):894-902.
46. Silva J.R.N., Camacho L.A.B., Siqueira M.M., Freire M.D.S., Castro Y.P., Maia M.D.L.S., et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine 2011, 29:6327-6334.
47. Reisler R.B., Danner D.K., Gibbs P.H. Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: using PRNT50 as an endpoint for immunogenicity. Vaccine 2010, 28:2436-2441.
48. Thomas S.J., Nisalak A., Anderson K.B., Libraty D.H., Kalayanarooj S., Vaughn D.W., et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance. Am J Trop Med Hyg 2009, 81:825-833.